Eye-stroke signals surface with Wegovy, but the risk remains very low and unproven
A British Journal of Ophthalmology study analyzed FDA adverse-event reports and found ischemic optic neuropathy (ION) in fewer than 1% of Wegovy users (28 of 3,070 reports) versus 47 of 20,608 for Ozempic, suggesting a possible Wegovy-specific signal but not proving causation. The data come from voluntary reports and don’t establish true risk; experts say the overall risk is very low and Wegovy’s benefits for weight management likely outweigh this potential issue. Regulators advise urgent medical care if eyesight worsens quickly, and Rybelsus showed no notable link in the study; dose differences remain unproven as a factor.
